Thinly traded Nightstar Therapeutics (NITE +8.4%) is up on almost double normal volume, albeit on turnover of only 198K shares. Earlier today, Leerink’s Joseph Schwartz raised his fair value target to $30 (40% upside) from $25.
The company develops gene therapies to treat retinal disorders. Lead candidate NSR-REP1 is in Phase 3 development for choroideremia, an inherited condition characterized by progressive vision loss. The initial symptom is night blindness, usually occurring in early childhood.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.